

A) Pertinent U.S. & European Studies with Sublingual Tablet Immunotherapy Constructs

■ Single Grass Allergen SLIT Tablet Construct [Timothy Grass Allergen Immunotherapy Tablet]

1. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2006; 117:802.
2. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2006; 118:434.
3. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. *Allergy* 2006; 61:185.
4. Calderón M, Essendrop M. Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. *J Investig Allergol Clin Immunol* 2006; 16:338.
5. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. *J Allergy Clin Immunol* 2008; 121:512.
6. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. *J Allergy Clin Immunol* 2010; 125:131.
7. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. *J Allergy Clin Immunol* 2009; 123:167.
8. Frølund L, Durham SR, Calderon M, et al. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. *Allergy* 2010; 65:753.
9. Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. *J Allergy Clin Immunol* 2011; 127:72.
10. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. *J Allergy Clin Immunol* 2011; 127:64.
11. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass allergy immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. *J Allergy Clin Immunol* 2012; 129:717-725.
12. Durham SR, Nelson HS, Nolte H, Bernstein DI, Creticos PS, Li Z, Andersen JS. Magnitude of Efficacy Measurements in Grass Allergy Immunotherapy Trials Is Highly Dependent on Pollen Exposure. (accepted: *Allergy* 2014).

■ Ragweed Allergen SLIT Tablet Construct [Ragweed Allergen Immunotherapy Tablet]

1. Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in N. American and European Adults. *J Allergy Clin Immunol* 2013; 131:1342-49.
2. Nolte H, Hebert J, Berman G, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. *Ann Allergy Asthma Immunol* 2013; 110:450-56.

■ Multiple Grass-allergen SLIT Tablet Construct [5-Grass Pollen Sublingual Tablet]

1. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. *JACI* 2007; 120:1338.
2. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2009; 123:160.
3. Malling HJ, Montagut A, Melac M, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. *Clin Exp Allergy* 2009; 39: 387
4. Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. *J Allergy Clin Immunol* 2011; 128:559.
5. Cox L, Casale T, Nayak A, Bernstein D, Creticos P, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE. *J Allergy Clin Immunol* 2012; 130:1327-34.

B) Pertinent Studies with Sublingual Liquid Immunotherapy Constructs in North America

1. Esch RE, Bush RK, Peden D, Lockey RF. Sublingual-oral administration of standardized allergenic extracts: phase I safety and dosing results. *Ann Allergy Asthma Immunol* 2008; 100:475.
2. Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. *J Allergy Clin Immunol* 2010; 125:660.
3. Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: results of a US trial. *J Allergy Clin Immunol* 2011; 127:974.
4. Creticos PS, Esch R, Couroux P, et al. A Randomized, Double-blind, Placebo-controlled, Parallel Trial of Standardized Short Ragweed (RW) Sublingual Allergy Immunotherapy Liquid Extract (RW-SAIL) in Adult Subjects with Ragweed-Induced Allergic Rhinoconjunctivitis. (jacionline.org; Dec 2013).
5. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. *Ann Allergy Asthma Immunol* 2004; 93:425-30.
6. Amar SM, Harbeck RJ, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. *J Allergy Clin Immunol* 2009; 124:150.
7. Andre C, Perrin-Fayolle M, Grosclaude M, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardised ragweed extract in patients with seasonal rhinitis, evidence for a dose-response relationship. *Allergy* 2002; 57(S73):31 [Europe]

C) Pertinent Studies Employing Immunostimulatory Adjuvants

1. Schroeder JT, Bieneman AP, Xia HQ, et al. TLR9 and FcεRI-Mediated Responses Oppose One Another in Plasmacytoid Dendritic Cells by Down-Regulating Receptor Expression. *J Imm* 2005; 175:5724-5731.
2. Chen YH, Bieneman AP, Creticos PS, et al. IFN-α Inhibits IL-3 Priming of Human Basophil Cytokine Secretion but not Leukotriene C4 and Histamine Release. *J Allergy Clin Immunol* 2003; 112:944-50.
3. Creticos PS, Schroeder JT, Chen Y. New Approaches in Immunotherapy: Allergen Vaccination with Immunostimulatory DNA. *Immunology and Allergy Clinics of North America*. 2004; 24: 569-81 [Review].
4. Moseman E, Liang X, Dawson A, et al. Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulated T Cells. *J Imm* 2004; 173:4433-42.
5. Tulic M, Fiset P, Christodoulou P, et al. Amb a 1-Immunostimulatory Oligodeoxynucleotide Conjugate Immunotherapy Decreases the Nasal Inflammatory Response. *J Allergy Clin Immunol* 2004; 113:235-41.
6. Creticos P, Schroeder J, Hamilton, R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. *N Engl J Med* 2006; 355: 1445-55.
7. Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well-tolerated grass pollen specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A (MPL), reduces allergic symptoms after only four preseasonal injections; *Allergy* 2001 56: 498-505.
8. Drachenberg KJ, Heinzkill M, Urban E, et al. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents; *Allerg et Immunopath* 2003.
9. Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. *Clin Exp Allergy* 2003; 33: 1198-1208.

10. Patel P, Salapatek A, Shah C, et al; The Safety and Clinical Efficacy of Pollinex Quattro Ragweed Assessed in an Environmental Exposure Chamber (EEC). *Ann Allergy Asthma Immunol* 2007; 3: 86.
11. DuBuske L, Frew A, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. *Allergy Asthma Proc* 2011; 32: 239-47.
12. Patel P, Holdich T, Drachenberg KJ, et al. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. *J Allergy Clin Immunol* 2014; 133:121-29.
13. Beeh K, Kannies F, Wagner F, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent asthma. *J Allergy Clin Immunol* 2013; 131:866-74.
14. Storni, Ruedl, Schwarz, et al. Nonmethylated CpG Motifs Packaged into Virus-like Particles Induce Protective Cytotoxic T Cell responses in the Absence of Systemic Side Effects. *J Immunol.* 2004
15. Kundig TM, Senti G, Schnetzler G, et al; J Allg Clin Imm. Der p 1 Peptide on Virus-like Particles is Safe and Highly Immunogenic in Healthy Adults. *J Allergy Clin Immunol* 2006; 117:1470-76.
16. Senti G, Johansen P, Haug S, et al. Use of A-type CpG Oligonucleotides as an Adjuvant in Allergen-specific Immunotherapy in Humans: a Phase I/II Clinical Trial. *Cx Et Experimental Allg* 2009 (39): 62-70.
17. Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of Clinical Efficacy of CYT003-QbG10 in Patients with Allergic Rhinoconjunctivitis: a Phase IIb Study. *Cx Et Experimental Allg* 2011 (41):1305-12.

D) Pertinent Studies with T Cell-tolerizing Peptide Immunotherapy

1. Norman P, Ohman J, Long A, Creticos P, et al. Treatment of cat allergy with T-cell reactive peptides 1996. *Am J Respir Crit Care Med*; 154: 1623-28.
2. Oldfield W, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. *Lancet* 2002; 360: 47-53.
3. Fellrath JM, Kettner A, Dufour N, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. *J Allergy Clin Immunol* 2003; 111:854-61.
4. Smith T, Alexander C, Kay AB, et al. Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25 T cells: a double-blind placebo-controlled study. *Allergy* 2004; 59: 1097-1101.
5. Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. *Allergy* 2005; 60:1269-74.
6. Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity. *PLoS Med* 2005; 2:e78.
7. Campbell J, Buckland K, McMillan S, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. *JEM* 2009; 206: 1535.
8. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. *J Allergy Clin Immunol* 2011; 127 (1):89-97.
9. Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment Effect 1 year after the start of dosing: A randomized, placebo-controlled study. *J Allergy Clin Immunol* 2013; 131(1): 103-109.
10. Worm M, Patel D, Creticos PS. Cat Peptide Antigen Desensitisation for Treating Cat Allergic Rhinoconjunctivitis. *Expert Opin. Investig. Drugs* 2013 (October); 22 (10): 1347-1357 [Review].

E) Intralymphatic Immunotherapy

1. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. *Proc Natl Acad Sci (USA)* 2008 ;105:17908–17912.
2. Senti G, Johansen P, Kundig. Intralymphatic immunotherapy. *Curr Opin Allergy Clin Immunol* 2009; 9:537-43.
3. Senti G, Cramer R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. *J Allergy Clin Immunol* 2012; 129:1290-96.
4. Hylander T, Latif L, Petersson U, Cardell L. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. *J Allergy Clin Immunol* 2013; 131:412-20.

F) Epicutaneous Immunotherapy

1. Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. *J Allergy Clin Immunol* 2009; 124: 997-1002.
2. Agostinis F, Forti S, Di Bernardino F. Grass transcutaneous immunotherapy in children with seasonal allergic rhinitis. *Allergy* 2010; 65: 410.
3. Senti G, von Moos S, Kündig T. Epicutaneous allergen administration: is this the future of allergen specific immunotherapy? *Allergy* 2011; 66(6): 798-809.
4. Senti G, von Moos S, Tay F, et al. *Epicutaneous* allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. *J Allergy Clin Immunol* 2012; 129: 128.

G) Recombinant Immunotherapy

1. Valenta R and Kraft D. From allergen structure to new forms of allergen-specific immunotherapy. *Review. Curr Opin Immunol.* 2002; 14 (6): 718-727.
2. Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. *Proc Natl Acad Sci USA.* 2004; 101: 14677-82.
3. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. *J Allergy Clin Immunol* 2005; 116: 608-13.
4. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. *J Allergy Clin Immunol.* 2008. 122(5): 951-60.
5. Valenta R, Linhart B, Swoboda I, Niederberger, V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. *Allergy* 2011; 66: 775-783.
6. Marth K, Shamji M, Swoboda I, et al. A Non-allergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. *Journal of Imm* 2013; 190(7): 3068-78.

E) General Background References

1. Wilson D, Torres-Lima M, Durham S. Sublingual immunotherapy for allergic rhinitis. *Cochrane Database of Systematic Reviews* 2003, Issue 2. (No.: CD002893).
2. Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. *J Allergy Clin Immunol* 2006; 117:1021.
3. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. *Allergy* 2007; 62(3): 317-24.
4. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy* 2008; 63 (Supp86):8-160.
5. Canonica GW, Bousquet J, Casale T, et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. *Allergy* 2009; 64 (Suppl 91) 91:1-59.
6. Casale TB, Canonica GW, Bousquet J, et al. Recommendations for appropriate sublingual immunotherapy clinical trials. *J Allergy Clin Imm* 2009; 124:665-70.
7. European Medicines Agency. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. London; 2009.
8. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter; 3rd update. *J Allergy Clin Immunol* 2011; 127 (1): S1-55.
9. Radulovic S, Wilson D, Calderon M, Durham S. Systemic reviews of sublingual immunotherapy (SLIT). *Allergy* 2011; 66:740-52.
10. Bousquet J, Schünemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA²LEN statement. *Allergy* 2011; 66: 765-774.
11. DiBona D, Plaia A, Leto-Barone M, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison. *J Allergy Clin Immunol* 2012; 130:1097-1107.
12. Bahceciler N and Galip N. Comparing subcutaneous and sublingual immunotherapy: what do we know? *Curr Opin Allergy Clin Immunol* 2012; 12:640-647.
13. Creticos PS. Legends in Allergy: Philip S. Norman and Lawrence M. Lichtenstein -The Hopkins Experience. *J Allergy Clin Immunol* 2007; 11:1031-8 [Review].
14. Creticos PS. Sublingual and oral immunotherapy for allergic rhinitis; In: UpToDate; Waltham, MA, Sept 2013 [Review].